Analysts Set Tempus AI, Inc. (NASDAQ:TEM) PT at $46.29

Shares of Tempus AI, Inc. (NASDAQ:TEM) have been assigned an average rating of “Buy” from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have covered the stock in the last year is $45.63.

Several analysts have recently issued reports on the company. William Blair started coverage on Tempus AI in a report on Tuesday, July 9th. They set an “outperform” rating on the stock. Needham & Company LLC assumed coverage on shares of Tempus AI in a research note on Tuesday, July 9th. They set a “buy” rating and a $47.00 price objective on the stock. Longbow Research assumed coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They issued a “buy” rating and a $48.00 target price for the company. Loop Capital started coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They set a “buy” rating and a $48.00 price target on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They set a “buy” rating and a $45.00 price objective for the company.

Tempus AI Stock Down 7.9 %

Shares of NASDAQ:TEM opened at $36.60 on Tuesday. Tempus AI has a 1 year low of $22.89 and a 1 year high of $43.88.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.